CollabRx, Inc (CLRX) - NASDAQ
  • Nov. 13, 2014, 4:28 PM
    • CollabRx (NASDAQ:CLRX): FQ2 EPS of -$0.35
    • Revenue of $176K (-29.9% Y/Y).
    | Nov. 13, 2014, 4:28 PM
  • Aug. 19, 2014, 5:06 PM
    • CollabRx (CLRX -2.8%fiscal Q1 results: Revenues: $64K (-76.3%); Operating Expenses: $1.3M (+36.9%); Net Loss: ($1.2M) (-56.6%); Loss Per Share: ($.61) (-48.8%); Quick Assets: $2.1M (+44.6%); Cash Burn: ($0.7M) (-20.0%).
    • Fiscal 2015 Guidance: quarterly cash operating expenses: ~$1M.
    | Aug. 19, 2014, 5:06 PM
  • Aug. 14, 2014, 4:28 PM
    • CollabRx (NASDAQ:CLRX): FQ1 EPS of -$0.61.
    • Revenue of $64K.
    | Aug. 14, 2014, 4:28 PM
  • Feb. 11, 2014, 5:10 PM
    • CollabRx (CLRX): Q4 EPS of -$0.52.
    • Revenue of $56K.
    | Feb. 11, 2014, 5:10 PM
Company Description
CollabRx Inc is a data analytics company. It is engaged in developing and delivering knowledge-based products and services that informs healthcare decision-making, with an emphasis on genomics-based 'precision' medicine and big data analytics.
Sector: Technology
Industry: Application Software
Country: United States